The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

Investing.com - TD Cowen has lowered its price target on Novo Nordisk (NYSE: NVO) to $70.00 from $105.00 while maintaining a Buy rating on the stock. The new target sits within the broader analyst ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

NEW YORK - August 20, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Novo ... and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and ...